News

Major stock indexes on Wall Street drifted to a mixed finish Friday, capping a rare bumpy week for the market. The benchmark index posted a loss for the week, its first after three straight weekly gains. The Dow Jones Industrial Average slipped 0.2%, while the Nasdaq composite rose 0.1%, ending just below the record high it set on Wednesday.

(Bloomberg) -- This year’s frontrunners, big technology stocks, set a record while Treasuries sank as investors braced for a slowdown in the pace of the Federal Reserve’s interest-rate cuts ahead of a meeting next week.Most Read from BloombergHong Kong's Expat Party Hub Reshaped by Chinese InfluxHow California Sees the World, and ItselfBrace for a Nationwide Shuffle of Corporate HeadquartersCity Hall Is HiringAmerican Institute of Architects CEO ResignsThe Nasdaq 100 climbed for the fourth week

(Bloomberg) -- The message from Nasdaq as the Black Lives Matter movement exploded across the US: push for diversity – or prepare to explain.Most Read from BloombergHong Kong's Expat Party Hub Reshaped by Chinese InfluxHow California Sees the World, and ItselfBrace for a Nationwide Shuffle of Corporate HeadquartersCity Hall Is HiringAmerican Institute of Architects CEO ResignsFour years later, a federal appeals court has struck down an attempt by Nasdaq’s US exchange – home of Apple Inc, Nvidia

Here’s what could be next for Atlassian stock.

(Bloomberg) -- Single-stock ETFs have been one of Wall Street’s hottest trades this year thanks to eye-popping returns and billions of dollars in inflows. Now, one issuer is kicking off a fee war in a bid to stand out and attract new cash. Most Read from BloombergHong Kong's Expat Party Hub Reshaped by Chinese InfluxHow California Sees the World, and ItselfBrace for a Nationwide Shuffle of Corporate HeadquartersCity Hall Is HiringAmerican Institute of Architects CEO ResignsLeverage Shares, which

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh

US benchmark equity indexes were lower after midday Friday as markets looked forward to the Federal